The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
|Videos|December 21, 2021
Dr. Vaishampayan highlights new options in second-line urothelial cancer
Author(s)Urology Times staff
Advertisement
Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine, professor of internal medicine, University of Michigan, discusses new options available for the second-line treatment of urothelial cancer, including the antibody-drug conjugates enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy).
Advertisement
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5